Product Description
Chlorthalidone is a medication used in the management and treatment of hypertension. It is in the thiazide-like diuretics class of drugs. Chlorthalidone is a thiazide-like sulfonamide-derived diuretic that has been FDA approved since 1960 for the management of hypertension. It is also used in the treatment of edema (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK553174/)
Mechanisms of Action: NCCT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | Lebanon | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Myocardial Infarction | Hypertension | Stroke | Liver Cirrhosis | Hypertension, Renal | Kidney Diseases | Nephrotic Syndrome | Edema | Myocardial Infarction | Hypertension | Stroke
Known Adverse Events: Hypotension | Dizziness
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, Mexico
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OPTION TREAT | P3 |
Recruiting |
Hypertension |
2023-12-31 |
|
| SIL-30601-III-20(1) | P3 |
Completed |
Hypertension |
2023-08-15 |
95% |
| SIL-30601-III-20(1) | P3 |
Completed |
Hypertension |
2023-08-15 |
95% |